Navigation Links
Roche Symposium Showcases Accomplishments of Next Generation of Chemists
Date:5/14/2008

- Outstanding Graduate Students and Professors Honored for Their Research -

PALO ALTO, Calif., May 14 /PRNewswire/ -- Roche has honored 12 outstanding Ph.D. students and two professors with the company's Excellence in Chemistry Award for research accomplishments in the field of organic chemistry. The winners participated in Roche's annual Chemistry Symposium where they gained a real-world perspective on the important role of organic chemistry in pharmaceutical discovery. This year's fifth annual symposium was held in Palo Alto on May 12 and 13. The event rotates annually between Roche research centers in Nutley, New Jersey, and Palo Alto, California.

"The Chemistry Symposium is a bridge between cutting-edge researchers in academia and at Roche and is intended to honor the accomplishments of the awardees and to demonstrate the importance of chemistry in creating new medicines," said Eric Sjogren, Ph.D., vice president, Roche Medicinal Chemistry. "We hope that this next generation of chemists leaves with a deeper understanding of the vital role organic chemistry plays in the pharmaceutical industry."

During the symposium, students discussed their research projects and were given overviews of the drug discovery process by Roche scientists. In addition, there were plenary lectures by this year's faculty award winners: Professor Jeffrey W. Bode of the University of Pennsylvania and Professor Dirk Trauner of the University of California, Berkeley. The awardees also heard case histories in medicinal and process chemistry and were given a tour of the Roche Palo Alto site.

Representing a range of prestigious institutions, the 12 winners this year were: Melissa Beenen (University of California, Berkeley), Landy K. Blasdel (Harvard University), Mark S. Chen (University of Illinois at Urbana-Champaign), John A. Enquist, Jr. (California Institute of Technology), Kami L. Hull (University of Michigan), Thomas J. Maimone (The Scripps Research Institute), Meredeth A. McGowan (Harvard University), Joshua G. Pierce (University of Pittsburgh), Nathan D. Shapiro (University of California, Berkeley), Eduardas Skucas (University of Texas at Austin), Vladimir Sofiyev (University of California, Berkeley), and Nicole White (University of California, Irvine).

The students were chosen by Roche chemists in Palo Alto and Nutley through a rigorous selection process. More than 45 faculty members at prominent U.S. universities were invited to nominate students to participate in the symposium. Professors were asked to consider students who might be interested in the pharmaceutical industry and who are one to two years from completing their Ph.D. The submissions required a supporting letter from the nominee, the student's resume and a short research summary. Besides the opportunity to attend and present their research projects at the Chemistry Symposium, the students each received a crystal award and an honorarium. Professors Bode and Trauner each received an unrestricted grant to support their ongoing research in addition to the honorarium.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. Located in Palo Alto, Calif., Roche Palo Alto LLC is one of the company's six pharmaceutical research centers. Here scientists focus on the discovery and early clinical development of innovative new medicines to treat inflammatory, respiratory and viral diseases. For more information on Roche, access http://www.roche.com or http://www.rocheusa.com.

Contact(s): Jacqueline Wallach Darien Wilson

650-855-6228 973-562-2232


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Roches Vidal Honored as 2008 HBA Rising Star
2. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
3. Media advisory - Neurochems Annual and Special Meeting of Shareholders April 15, 2008
4. Neurochem Annual and Special Meeting of shareholders
5. Rochester Medical Applauds Improved U.S. Medicare Coverage Policy for Intermittent Catheters
6. Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
7. Roche Statement Regarding Tamiflu U.S. Label Revision
8. Neurochem announces departure of two members of management team
9. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
10. Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide
11. Roche Completes Tender Offer for Ventana Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... The OSHA Training ... Institute Education Center headquartered in Northern California, has issued an important reminder to ... their worksites. Employers with workers exposed to high temperatures should establish a ...
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology: